Floatz logo

bp1001

Chronic Myelogenous Leukemia, Ph1-Positive

Bio-Path Holdings, Inc.nucleic_acidPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

86 Active assets in the Chronic Myelogenous Leukemia, Ph1-Positive cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
City of Hope Medical Center
Phase 3BBB
Nilotinib
Novartis Pharmaceuticals
Phase 4BBB
Fludarabine
Fred Hutchinson Cancer Center
Phase 3BBB
Therapeutic Allogeneic Lymphocytes
University of Chicago
Phase 2BBB
Romidepsin
Center for International Blood and Marrow Transplant Research
Phase 2BBB

View all 50 →

Same molecule, other indications

bp1001 is also rated in:

acute myeloid leukemiaDormant
CCC
Indicative ·
54 / 100
View asset →
myelodysplastic syndromeDormant
CCC
Indicative ·
51 / 100
View asset →
Ph1 Positive CMLDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →